CN103974955B - 嘧啶并-哒嗪酮化合物及其用途 - Google Patents
嘧啶并-哒嗪酮化合物及其用途 Download PDFInfo
- Publication number
- CN103974955B CN103974955B CN201280051788.8A CN201280051788A CN103974955B CN 103974955 B CN103974955 B CN 103974955B CN 201280051788 A CN201280051788 A CN 201280051788A CN 103974955 B CN103974955 B CN 103974955B
- Authority
- CN
- China
- Prior art keywords
- bases
- amino
- pyridazine
- phenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **N1C(*)C(*)*C(*)C1* Chemical compound **N1C(*)C(*)*C(*)C1* 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810492306.1A CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526525P | 2011-08-23 | 2011-08-23 | |
| US61/526,525 | 2011-08-23 | ||
| PCT/US2012/051980 WO2013028818A1 (en) | 2011-08-23 | 2012-08-23 | Pyrimido- pyridazinone compounds and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810492306.1A Division CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103974955A CN103974955A (zh) | 2014-08-06 |
| CN103974955B true CN103974955B (zh) | 2018-06-19 |
Family
ID=46829884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280051788.8A Active CN103974955B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
| CN201810492306.1A Active CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810492306.1A Active CN108707151B (zh) | 2011-08-23 | 2012-08-23 | 嘧啶并-哒嗪酮化合物及其用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8729079B2 (enExample) |
| EP (4) | EP4327886A3 (enExample) |
| JP (1) | JP5993010B2 (enExample) |
| CN (2) | CN103974955B (enExample) |
| BR (1) | BR112014003981A2 (enExample) |
| CA (1) | CA2846187A1 (enExample) |
| DK (2) | DK3392252T3 (enExample) |
| ES (2) | ES2690971T3 (enExample) |
| FI (1) | FI3392252T3 (enExample) |
| HU (1) | HUE065564T2 (enExample) |
| IL (1) | IL231082A (enExample) |
| MX (1) | MX361458B (enExample) |
| PL (1) | PL2748166T3 (enExample) |
| WO (1) | WO2013028818A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707151A (zh) * | 2011-08-23 | 2018-10-26 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| CN118105392A (zh) * | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
| CN111961035B (zh) * | 2019-05-20 | 2022-11-01 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
| CN114174298B (zh) * | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN113583026B (zh) * | 2020-04-30 | 2024-06-14 | 杭州英创医药科技有限公司 | 一类含有稠合三环结构的化合物 |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| AU2022421224A1 (en) * | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| JP2025506783A (ja) * | 2022-02-23 | 2025-03-13 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | グサシチニブの固体形態 |
| WO2023192989A2 (en) * | 2022-04-01 | 2023-10-05 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
| WO2025020171A1 (en) * | 2023-07-27 | 2025-01-30 | Libertas Bio, Inc. | Crystalline forms of a jak/syk inhibitor |
| AU2024299978A1 (en) | 2023-07-27 | 2026-03-12 | Libertas Bio, Inc. | Solid state forms of gusacitinib |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756508A (fr) * | 1969-09-24 | 1971-03-01 | Takeda Chemical Industries Ltd | Derives de pyrimidopyridazine |
| CA1004223A (en) * | 1972-05-12 | 1977-01-25 | Theodor Denzel | Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters |
| JPS4948695U (enExample) | 1972-07-29 | 1974-04-27 | ||
| JPS50101387A (enExample) * | 1974-01-16 | 1975-08-11 | ||
| CA1052046A (en) | 1974-01-21 | 1979-04-03 | American Cyanamid Company | Unsymmetrically substituted 1,4-dioxane-2,5-diones |
| US5369086A (en) | 1993-04-28 | 1994-11-29 | Zeneca Limited | N-benzotriazoles |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| JPH0948695A (ja) | 1995-08-02 | 1997-02-18 | Toshiba Ceramics Co Ltd | シリコン単結晶の製造方法 |
| JP2002504550A (ja) | 1998-02-25 | 2002-02-12 | ファルマシア・アンド・アップジョン・カンパニー | 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体 |
| JP3635238B2 (ja) | 1998-11-10 | 2005-04-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖの複製を阻害するピリミジン類 |
| PL207755B1 (pl) * | 2000-09-22 | 2011-01-31 | N V Organon | Bicykliczny związek heteroaromatyczny, zawierająca go kompozycja farmaceutyczna i jego zastosowania |
| WO2002088095A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| AU2003212634A1 (en) | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| CA2577467C (en) | 2004-09-30 | 2013-05-28 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
| WO2006066361A1 (en) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
| EP1869037B1 (en) | 2005-03-25 | 2011-07-27 | Tibotec Pharmaceuticals | Heterobicylic inhibitors of hvc |
| US20080194656A1 (en) | 2005-04-29 | 2008-08-14 | Monique Jenny Marie Berwaer | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| US20070161670A1 (en) | 2006-01-09 | 2007-07-12 | Bristol-Myers Squibb Company | Process for the preparation of substituted heterocycles |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
| PT2698062E (pt) * | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| KR20090130051A (ko) | 2007-03-14 | 2009-12-17 | 엑셀리시스, 인코포레이티드 | 헤지호그 경로의 억제제 |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| JP2012506386A (ja) | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| MX2012004846A (es) * | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| WO2011079105A1 (en) * | 2009-12-23 | 2011-06-30 | Abbott Laboratories | Novel thienopyrrole compounds |
| US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| EP4327886A3 (en) * | 2011-08-23 | 2024-05-22 | Libertas Bio, Inc. | Pyrimido- pyridazinone compounds and use thereof |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| CN118105392A (zh) * | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
-
2012
- 2012-08-23 EP EP23201319.3A patent/EP4327886A3/en active Pending
- 2012-08-23 DK DK18175788.1T patent/DK3392252T3/da active
- 2012-08-23 HU HUE18175788A patent/HUE065564T2/hu unknown
- 2012-08-23 ES ES12756865T patent/ES2690971T3/es active Active
- 2012-08-23 CN CN201280051788.8A patent/CN103974955B/zh active Active
- 2012-08-23 EP EP18175788.1A patent/EP3392252B1/en active Active
- 2012-08-23 MX MX2014002112A patent/MX361458B/es active IP Right Grant
- 2012-08-23 EP EP12756865.7A patent/EP2748166B1/en active Active
- 2012-08-23 ES ES18175788T patent/ES2969977T3/es active Active
- 2012-08-23 CN CN201810492306.1A patent/CN108707151B/zh active Active
- 2012-08-23 PL PL12756865T patent/PL2748166T3/pl unknown
- 2012-08-23 WO PCT/US2012/051980 patent/WO2013028818A1/en not_active Ceased
- 2012-08-23 JP JP2014527282A patent/JP5993010B2/ja active Active
- 2012-08-23 BR BR112014003981A patent/BR112014003981A2/pt not_active IP Right Cessation
- 2012-08-23 EP EP18182723.9A patent/EP3404029A3/en not_active Withdrawn
- 2012-08-23 DK DK12756865.7T patent/DK2748166T3/en active
- 2012-08-23 FI FIEP18175788.1T patent/FI3392252T3/fi active
- 2012-08-23 US US13/592,511 patent/US8729079B2/en active Active
- 2012-08-23 CA CA2846187A patent/CA2846187A1/en active Pending
-
2014
- 2014-02-23 IL IL231082A patent/IL231082A/en active IP Right Grant
- 2014-04-03 US US14/244,183 patent/US9382277B2/en active Active
-
2016
- 2016-04-25 US US15/137,950 patent/US10183944B2/en active Active
-
2018
- 2018-11-30 US US16/206,395 patent/US10647720B2/en active Active
-
2020
- 2020-02-25 US US16/800,111 patent/US20200190095A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108707151A (zh) * | 2011-08-23 | 2018-10-26 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103974955A (zh) | 嘧啶并-哒嗪酮化合物及其用途 | |
| JP5188988B2 (ja) | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 | |
| KR101483215B1 (ko) | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 | |
| US20100204221A1 (en) | Pyrrolopyrimidinyl axl kinase inhibitors | |
| WO2008106635A1 (en) | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors | |
| WO2018187294A1 (en) | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof | |
| WO2010011349A2 (en) | Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use | |
| WO2023279938A1 (zh) | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 | |
| CN119790043A (zh) | 三环类化合物及其应用 | |
| CN111961035B (zh) | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 | |
| KR102046196B1 (ko) | 이미다조피리딘 유도체의 치료적 용도 | |
| CN103534252B (zh) | 苯并吗啉衍生物及其制备方法和应用 | |
| WO2019109647A1 (zh) | 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂 | |
| HK40000773A (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| HK40107186A (en) | Pyrimido- pyridazinone compounds and use thereof | |
| CN113150012B (zh) | 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途 | |
| HK1262920A1 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| HK1262920B (en) | Pyrimido- pyridazinone compounds and use thereof | |
| CN101374842A (zh) | 作为药物剂的氮杂卓并吲哚衍生物 | |
| KR20070045063A (ko) | 항종양 활성을 갖는〔1,2,4〕―트리아졸로〔4,3―ｃ〕퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170323 Address after: New jersey, USA Applicant after: Asana BioSciences, LLC Address before: American Pennsylvania Applicant before: ENDO PHARMACEUTICALS INC. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220727 Address after: new jersey Patentee after: ABS development 1 Co.,Ltd. Address before: new jersey Patentee before: Asana BioSciences, LLC |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Liberty Biology Co.,Ltd. Address before: new jersey Patentee before: ABS development 1 Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |